SAN DIEGO,
Feb. 4, 2016 /PRNewswire/
-- ResMed (NYSE:RMD), the world's leading innovator in
sleep-disordered breathing and respiratory care, today announced it
completed the acquisition of Inova Labs Inc., a privately-held
medical device company that develops and commercializes innovative
oxygen therapy products.
"We are excited to complete this acquisition, which
expands our offerings and solutions to address a global COPD
epidemic impacting tens of millions of people," said
Mick Farrell, CEO of
ResMed. "This acquisition is an important step to reach our
goal of improving 20 million lives by 2020."
ResMed's current respiratory care offerings include
world-leading patient interface products, the AirCurve™ 10 series
of cloud-connected non-invasive ventilators, the Stellar™ series of
non-invasive ventilators, and the flagship Astral™ series. The
Astral is ResMed's award-winning lightweight non-invasive life
support platform, with internal and external batteries that provide
up to 24 hours of freedom for patients.
With the acquisition of Austin,
Texas-based Inova Labs,
ResMed's respiratory care portfolio now encompasses both innovative
portable oxygen concentrators and stationary options for the home.
Key products include:
- LifeChoice Activox – lightweight, portable oxygen
concentrators that lead the industry in offering extended battery
life for freedom and mobility.
- Activox DUO2 – the industry's first fully integrated
stationary and portable oxygen concentrator system.
The transaction's financial terms were not
disclosed.
About ResMed
The global team at
ResMed (NYSE:RMD) is united in the commitment to change millions of
lives with every breath. With more than 4,000 employees and a
presence in over 100 countries, the company has pioneered
innovative devices for the diagnosis, treatment and management of
sleep-disordered breathing, chronic obstructive pulmonary disease
and other chronic conditions for more than 25 years. ResMed's
world-leading products and connected healthcare solutions improve
the quality of life for millions of patients worldwide, reduce the
impact of chronic disease and save healthcare costs. For more
information about ResMed and its businesses, visit
www.resmed.com or follow @resmed on
Twitter and Facebook.
|
ResMed Contacts:
|
|
For News Media
|
For
Investors
|
|
Alison Graves
|
Agnes Lee
|
|
Global Corporate
Communications
|
Senior Director,
Investor Relations
|
|
O: +1 (858) 836-6789
|
O: +1 (858)
836-5971
|
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/resmed-completes-acquisition-of-inova-labs-300214690.html
SOURCE ResMed Inc.